June 2016 Updated Crosswalk:
|
|
|
- Gervais Douglas
- 7 years ago
- Views:
Transcription
1 June 2016 Updated Crosswalk: 2016 HCPCS G0279 G6001 G6002 G6003 G6004 deleted f Radiology Coding BCBSNC currently considers this service investigational and will not cover either the HCPCS CPT s. Diagnostic digital breast tomosynthesis, unilateral bilateral (list separately in addition to G0204 G0206) Ultrasonic guidance f placement of radiation therapy fields Stereoscopic X-ray guidance f localization of target volume f the delivery of radiation therapy Radiation treatment delivery, single treatment area, single pt parallel opposed pts, simple blocks no blocks: up to 5MeV Radiation treatment delivery, single treatment area, single pt parallel opposed pts, simple blocks no blocks: 6-10MeV Radiation Therapy Coding BCBSNC will reimburse f HCPCS (G ) CPT, but not both, f the same date of service DIGITAL BREAST TOMOSYNTHESIS; BILATERAL DIGITAL BREAST TOMOSYNTHESIS; UNILATERAL GUIDANCE F LOCALIZATION OF TARGET VOLUME F DELIVERY OF RADIATION TREATMENT DELIVERY, INCLUDES INTRAFRACTION TRACKING, WHEN PERFMED GUIDANCE F LOCALIZATION OF TARGET VOLUME F DELIVERY OF RADIATION TREATMENT DELIVERY, INCLUDES INTRAFRACTION TRACKING, WHEN PERFMED RADIATION TREATMENT DELIVERY, >1 MEV; SIMPLE RADIATION TREATMENT DELIVERY, >1 MEV; SIMPLE Page 1 of 18
2 G6005 G6006 G6007 G6008 G6009 G6010 G6011 Radiation treatment delivery, single treatment area, single pt parallel opposed pts, simple blocks no blocks: 11-19MeV Radiation treatment delivery, single treatment area, single pt parallel opposed pts, simple blocks no blocks: 20 MeV greater Radiation treatment delivery, 2 separate treatment areas, 3 me pts on a single treatment area, use of multiple blocks; up to 5MeV Radiation treatment delivery, 2 separate treatment areas, 3 me pts on a single treatment area, use of multiple blocks; 6-10MeV Radiation treatment delivery, 2 separate treatment areas, 3 me pts on a single treatment area, use of multiple blocks; 11-19MeV Radiation treatment delivery, 2 separate treatment areas, 3 me pts on a single treatment area, use of multiple blocks; 20 MeV greater Radiation treatment delivery,3 me separate treatment areas, custom blocking, tangential pts, wedges, rotational beam, compensats, electron beam; up to 5MeV deleted f RADIATION TREATMENT DELIVERY, >1 MEV; SIMPLE RADIATION TREATMENT DELIVERY, >1 MEV; SIMPLE RADIATION TREATMENT DELIVERY, >1 MEV; INTERMEDIATE RADIATION TREATMENT DELIVERY, >1 MEV; INTERMEDIATE RADIATION TREATMENT DELIVERY, >1 MEV; INTERMEDIATE RADIATION TREATMENT DELIVERY, >1 MEV; INTERMEDIATE RADIATION TREATMENT DELIVERY, >1 MEV; COMPLEX Page 2 of 18
3 G6012 G6013 G6014 G6015 (requires preauthization) G6016 (requires preauthization) Radiation treatment delivery,3 me separate treatment areas, custom blocking, tangential pts, wedges, rotational beam, compensats, electron beam; 6-10MeV Radiation treatment delivery,3 me separate treatment areas, custom blocking, tangential pts, wedges, rotational beam, compensats, electron beam; 11-19MeV Radiation treatment delivery,3 me separate treatment areas, custom blocking, tangential pts, wedges, rotational beam, compensats, electron beam; 20MeV greater Intensity modulated treatment delivery, single multiple fields/arcs, via narrow spatially and tempally modulated beams, binary, dynamic MLC, per treatment session Compensat-based beam modulation treatment delivery of inverse planned treatment using 3 me high resolution (milled cast) compensat, convergent beam modulated fields, per treatment session deleted f (requires pre-authization) (requires pre-authization) (requires pre-authization) RADIATION TREATMENT DELIVERY, >1 MEV; COMPLEX RADIATION TREATMENT DELIVERY, >1 MEV; COMPLEX RADIATION TREATMENT DELIVERY, >1 MEV; COMPLEX INTENSITY MODULATED RADIATION TREATMENT DELIVERY (IMRT), INCLUDES GUIDANCE AND TRACKING, WHEN PERFMED; SIMPLE INTENSITY MODULATED RADIATION TREATMENT DELIVERY (IMRT), INCLUDES GUIDANCE AND TRACKING, WHEN PERFMED; COMPLEX INTENSITY MODULATED RADIATION TREATMENT DELIVERY (IMRT), INCLUDES GUIDANCE AND TRACKING, WHEN PERFMED; SIMPLE Page 3 of 18
4 deleted f G0477 G0478 Drug Toxicology Coding BCBSNC will reimburse f one HCPCS (G ) one CPT in the same categy, but not both, f the same date of service Drug tests(s), presumptive, any number of drug classes; any number of devices procedures, (eg, immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when perfmed, per date of service. Drug tests(s), presumptive, any number of drug classes; any number of devices procedures, (eg, immunoassay) read by instrument-assisted direct optical observation (eg, dipsticks, cups, cards, cartridges), includes sample validation when perfmed, per date of service. G0434 G0434 Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test moderate complexity test, per patient encounter Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test moderate complexity test, per patient encounter DRUG SCREEN, ANY NUMBER OF DRUG CLASSES FROM DRUG CLASS LIST A; ANY NUMBER OF NON-TLC DEVICES PROCEDURES, (EG, IMMUNOASSAY) CAPABLE OF BEING READ BY DIRECT OPTICAL OBSERVATION, INCLUDING INSTRUMENTED- ASSISTED WHEN PERFMED (EG, DIPSTICKS, CUPS, CARDS, CARTRIDGES), PER DATE OF SERVICE DRUG SCREEN, ANY NUMBER OF DRUG CLASSES FROM DRUG CLASS LIST A; SINGLE DRUG CLASS METHOD, BY INSTRUMENTED TEST SYSTEMS (EG, DISCRETE MULTICHANNEL CHEMISTRY ANALYZERS UTILIZING IMMUNOASSAY ENZYME ASSAY), PER DATE OF SERVICE Page 4 of 18
5 G0479 G0480 Drug tests(s), presumptive, any number of drug classes; any number of devices procedures by instrumented chemistry analyzers (eg, immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when perfmed, per date of service tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 1-7 drug class(es), including metabolite(s) if perfmed deleted f G0434 G0434 Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test moderate complexity test, per patient encounter Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test moderate complexity test, per patient encounter DRUG SCREEN, PRESUMPTIVE, SINGLE DRUG CLASS FROM DRUG CLASS LIST B, BY IMMUNOASSAY (EG, ELISA) NON-TLC CHROMATOGRAPHY WITHOUT MASS SPECTROMETRY (EG, GC, HPLC), EACH PROCEDURE DRUG SCREEN, ANY NUMBER OF DRUG CLASSES, PRESUMPTIVE, SINGLE MULTIPLE DRUG CLASS METHOD; THIN LAYER CHROMATOGRAPHY PROCEDURE(S) (TLC) (EG, ACID, NEUTRAL, ALKALOID PLATE), PER DATE OF SERVICE Drug screen, any number of drug classes, presumptive, single multiple drug class method; not otherwise specified presumptive procedure (eg, TOF, MALDI, LDTD, DESI, DART), each procedure GABAPENTIN, NON-BLOOD HEROIN METABOLITE Page 5 of 18
6 G0481 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 8-14 drug class(es), including metabolite(s) if perfmed deleted f G0482 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative drug class(es), including metabolite(s) if perfmed.) G0434 Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test moderate complexity test, per patient encounter KETAMINE AND NKETAMINE METHYLENEDIOXYAMPHETAMINES (MDA, MDEA, MDMA) METHYLPHENIDATE Page 6 of 18
7 deleted f PREGABALIN G0483 tandem) and LC/MS (any type, single tandem and excluding PROPOXYPHENE dehydrogenase)); qualitative 22 me drug class(es), including metabolite(s) if perfmed STIMULANTS, SYNTHETIC G0480 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 1-7 drug class(es), including G0434 Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test moderate complexity test, per patient encounter ANTIDEPRESSANTS, SEROTONERGIC CLASS; 1 2 Page 7 of 18
8 metabolite(s) if perfmed deleted f ANTIDEPRESSANTS, SEROTONERGIC CLASS; 3-5 G0481 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 8-14 drug class(es), including metabolite(s) if perfmed ANTIDEPRESSANTS, SEROTONERGIC CLASS; 6 ME BUPRENPHINE CANNABINOIDS, NATURAL Drug screen, other than chromatographic; any number of G0482 G0434 drug classes, by CLIA waived test tandem) and LC/MS (any type, moderate complexity test, per CANNABINOIDS, SYNTHETIC; 1-3 single tandem and excluding patient encounter dehydrogenase)); qualitative Page 8 of 18
9 G0483 G drug class(es), including metabolite(s) if perfmed.). tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 22 me drug class(es), including metabolite(s) if perfmed tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative deleted f G0431 Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter CANNABINOIDS, SYNTHETIC; CANNABINOIDS, SYNTHETIC; 7 ME STEREOISOMER (ENANTIOMER) ANALYSIS, SINGLE DRUG CLASS Page 9 of 18
10 G0481 G drug class(es), including metabolite(s) if perfmed. tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 8-14 drug class(es), including metabolite(s) if perfmed tandem) and LC/MS (any type, single tandem and excluding deleted f G6030 G6032 G6034 G6036 G6037 G6030 G6032 G6034 G6036 G6037 Assay of amitriptyline Assay of desipramine Assay of doxepin Assay of imipramine Assay of ntriptyline Assay of amitriptyline Assay of desipramine Assay of doxepin Assay of imipramine Assay of ntriptyline ANTIDEPRESSANTS, TRICYCLIC AND OTHER CYCLICALS; 1 2 ANTIDEPRESSANTS, TRICYCLIC AND OTHER CYCLICALS; 3-5 ANTIDEPRESSANTS, TRICYCLIC AND OTHER CYCLICALS; 6 ME ANTIDEPRESSANTS, NOT OTHERWISE SPECIFIED Page 10 of 18
11 dehydrogenase)); qualitative drug class(es), including metabolite(s) if perfmed.) deleted f ANTIDEPRESSANTS, TRICYCLIC AND OTHER CYCLICALS; 1 2 G0483 G0480 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 22 me drug class(es), including metabolite(s) if perfmed tandem) and LC/MS (any type, single tandem and excluding G6031 G6051 G6035 Assay of benzodiazepines Assay of flurazepam Assay of gold BENZODIAZEPINES; BENZODIAZEPINES; 13 ME DRUG(S) SUBSTANCE(S), DEFINITIVE, QUALITATIVE QUANTITATIVE, NOT OTHERWISE SPECIFIED; 1-3 DRUG(S) SUBSTANCE(S), DEFINITIVE, QUALITATIVE QUANTITATIVE, NOT OTHERWISE SPECIFIED; 4-6 DRUG(S) SUBSTANCE(S), DEFINITIVE, QUALITATIVE QUANTITATIVE, NOT OTHERWISE SPECIFIED; 7 ME Page 11 of 18
12 dehydrogenase)); qualitative 1-7 drug class(es), including metabolite(s) if perfmed deleted f G6038 Or G6039 Assay of salicylate Assay of acetaminophen ANALGESICS, NON-OPIOID; ANALGESICS, NON-OPIOID; ANALGESICS, NON-OPIOID; 6 ME G0481 G0482 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 8-14 drug class(es), including metabolite(s) if perfmed G6040 G6050 G6041 G6055 G6042 Assay of alcohol (ethanol); any specimen except breath Assay of ethchlvynol Alkaloids, urine, quantitative Assay of nicotine Amphetamine methamphetamine ALCOHOLS ALCOHOL BIOMARKERS; ALCOHOL BIOMARKERS; 3 ME ALKALOIDS, NOT OTHERWISE SPECIFIED AMPHETAMINES; 1 2 Page 12 of 18
13 G0483 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative drug class(es), including metabolite(s) if perfmed.) tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 22 me drug class(es), including metabolite(s) if perfmed deleted f AMPHETAMINES; AMPHETAMINES; 5 ME Page 13 of 18
14 G0480 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 1-7 drug class(es), including metabolite(s) if perfmed deleted f G6043 G6044 Barbiturates, not elsewhere specified Cocaine metabolite BARBITURATES COCAINE G0481 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 8-14 drug class(es), including metabolite(s) if perfmed G6045 G6046 G6056 Assay of dihydroinone Assay of dihydromphinone Opiate(s), drug and metabolites, each procedure OPIATES, 1 ME Page 14 of 18
15 deleted f OPIOIDS AND OPIATE ANALOGS; OPIOIDS AND OPIATE ANALOGS; OPIOIDS AND OPIATE ANALOGS; 5 ME ANABOLIC STEROIDS; 1 2 G0482 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative drug class(es), including metabolite(s) if perfmed.) G6047 G6049 Assay of dihydrotestosterone Assay of epiandrosterone ANABOLIC STEROIDS; 3 ME G0483. tandem) and LC/MS (any type, single tandem and excluding G6048 Assay of dimethadione ANTIEPILEPTICS, NOT OTHERWISE SPECIFIED; ANTIEPILEPTICS, NOT OTHERWISE SPECIFIED; ANTIEPILEPTICS, NOT OTHERWISE SPECIFIED; 7 ME Page 15 of 18
16 dehydrogenase)); qualitative 22 me drug class(es), including metabolite(s) if perfmed deleted f G6054 Assay of methsuximide G0480 G0481 G6050 Assay of ethchlvynol SEDATIVE HYPNOTICS (NON-BENZODIAZEPINES) SKELETAL MUSCLE RELAXANTS; 1 2 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 1-7 drug class(es), including metabolite(s) if perfmed G6052 Assay of meprobamate SKELETAL MUSCLE RELAXANTS; 3 ME. G6053 Methadone METHADONE G6041 G6055 Alkaloids, urine, quantitative Assay of nicotine ALKALOIDS, NOT OTHERWISE SPECIFIED Page 16 of 18
17 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 8-14 drug class(es), including metabolite(s) if perfmed deleted f G0482. G6056 Opiate(s), drug and metabolites, each procedure tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative drug class(es), including metabolite(s) if perfmed.) FENTANYL OXYCODONE TAPENTADOL TRAMADOL Page 17 of 18
18 G0483 tandem) and LC/MS (any type, single tandem and excluding dehydrogenase)); qualitative 22 me drug class(es), including metabolite(s) if perfmed deleted f G6057 Assay of phenothiazine ANTIPSYCHOTICS, NOT OTHERWISE SPECIFIED; ANTIPSYCHOTICS, NOT OTHERWISE SPECIFIED; 4-6 ANTIPSYCHOTICS, NOT OTHERWISE SPECIFIED; ME Page 18 of 18
Clinical Drug Screening and/or Drug Testing
Manual: Policy Title: Reimbursement Policy Clinical Drug Screening and/or Drug Testing Section: Laboratory & Pathology Subsection: None Date of Origin: 10/26/2011 Policy Number: RPM016 Last Updated: 1/8/2016
PAYMENT POLICY STATEMENT
PAYMENT POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 01/01/2014 04/05/2017 04/05/2016 Policy Name Policy Number Drug Screening Tests PY-0020 Policy Type
Toxicology CPT Code Changes for 2016
Beginning January 1, 2016, CMS deleted all 2015 drug testing G codes and will continue to not recognize the AMA CPT codes for drug testing. CMS created three G codes for presumptive testing and four G
Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment
Clinical Position Statement Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment CLINICAL POSITION STATEMENT In most cases, immunoassay (qualitative) drug testing is sufficient for
The CPT code for Human papillomavirus (HPV) has changed from 87621 to 87624. This code (87624) covers testing for HPV High Risk genotypes.
January 2015 2015 CPT Code Updates Dear Client: The American Medical Association (AMA) publishes the Current Procedural Terminology (CPT) Coding Manual on an annual basis. For 2015, the AMA made several
July 1, 2015 VIA EMAIL
July 1, 2015 VIA EMAIL Marc Hartstein Director, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Mail Stop C4-01-26 Baltimore, MD 21244 Dear Marc:
Section: Laboratory Last Reviewed Date: December 2015. Policy No: 68 Effective Date: April 1, 2016
Medical Policy Manual Topic: Urine Drug Testing for Substance Abuse and Chronic Pain Date of Origin: December 2015 Section: Laboratory Last Reviewed Date: December 2015 Policy No: 68 Effective Date: April
Name of Policy: Urine Drug Testing in Pain Management
Name of Policy: Urine Drug Testing in Pain Management Policy #: 566 Latest Review Date: February 2015 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule, benefits are payable
Complex 2015 Changes to Radiation Oncology Coding
Complex 2015 Changes to Radiation Oncology Coding The Centers for Medicare & Medicaid Services (CMS) issued its Final Rule on October 31 outlining the codes it would recognize in calendar year (CY) 2015.
Contractor Information
Local Coverage Determination (LCD): Controlled Substance Monitoring and Drugs of Abuse Testing (L35006) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Number 2.04.513 Effective Date April 1, 2016 Revision Date(s) 05/04/16; 03/09/16; 04/24/15; 8/11/14 Replaces 2.04.98 (not adopted)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES CODING DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES APPENDIX HISTORY Drug Testing in Pain Management and Substance Abuse Treatment
2015 CPT Code Changes ACL Test
Changes ACL Test Test Description UCOMP DRUG SCREEN COMPLETE 80100 80303 G0431 UDINV DRUG INVESTIGATION 80100 80303 G0431 UTLC THIN LAYER CHROMATOGRAPHY DRUG SCREEN 80100 80303 G0431 UNIC NICOTINE, URINE
Tests Impacted by 2015 CPT Changes
Toxicology Changes for 2015 HPV Examples of Toxicology Panels Molecular Pathology, FISH and Anatomic Pathology 1 Toxicology Changes for 2015 80100 Test Code Dos Test Name 2015 2015 Medicare 5229 Drug Screen,
Collection Instructions for ARUP Drug Screen Kit #49204
Collection Instructions for ARUP Drug Screen Kit #49204 Manufacturer Purpose of Kit / Reagent (tests) Kit / Reagent Contents (list components) Other Supplies Needed ARUP Laboratories For Point of Collection
Toxicology/DAU Testing by Mass Spectrometry
Toxicology/DAU Testing by Mass Spectrometry AACC Conference: Mass Spectrometry in the Clinical Lab September 17, 2013 Kara Lynch, PhD, DABCC University of California San Francisco Disclosures Research
MVP/Care Core National 2015 Radiation Therapy Prior Authorization List (Effective January 1, 2015)
MVP/Care Core National 2015 Radiation Therapy Prior Authorization List (Effective January 1, 2015) CODE CODE TYPE Description 0330 REVCODE RADIOLOGY/THERAPEUTIC - GENERAL CLASSIFICATION 0333 REVCODE RADIOLOGY/THERAPEUTIC
DUI in Southern Ohio MATT 2006
DUI in Southern Ohio MATT 2006 Laureen J. Marinetti, M.S., Ph.D. Chief Toxicologist Montgomery County Coroner s s Office & Miami Valley Regional Crime Lab (MVRCL) Dayton, Ohio Region The MVRCL is a regional
PtProtect Pain Medication Management Program Monitors Patient Compliance
PHYSICIAN UPDATE 2013 Edition PtProtect Pain Medication Management Program Monitors Patient Compliance The PtProtect (Patient Protect) program offers pain medication management panels designed to improve
The Facts on Equine Drug Testing
The Facts on Equine Drug Testing CONTACT Travis Mays, MS Interim Section Head Analytical Chemistry, Drug Testing Laboratory Toxicology Laboratory 979.845.3414 tmays@ LIMITATIONS IN DRUG TESTING While advancements
An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse
Drug Testing An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse Printed on August 18, 2016 1:59 pm CST 2016 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.
Radiation Oncology Centers Participating in MassHealth. Daniel Tsai, Assistant Secretary and Director of MassHealth
Executive Office of Health and Human s Office of Medicaid www.mass.gov/masshealth May 2015 TO: FROM: RE: Radiation Oncology Centers Participating in Daniel Tsai, Assistant Secretary and Director of (2015
Urine Drug Toxicology and Pain Management Testing. Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA
Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives Describe what chronic pain is, who is affected and
Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center
Clinical Chemistry / POC Testing f o r Dr u g s o f Ab u s e in t h e ED Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center
Pain Medication Management Program Monitors Patient Compliance
PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your
Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction
Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction Drug testing beyond the health care and criminal justice systems has
Comprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine
Comprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine Application Note Authors Peter JW Stone and Kevin McCann Agilent Technologies, Inc. Santa Clara,
The potential of oral fluid as a specimen in various drug testing programs
The potential of oral fluid as a specimen in various drug testing programs *Christine Moore, Cynthia Coulter, Katherine Crompton, Warren Rodrigues, Michael Vincent, James Soares Immunalysis Corporation,
What Does the Drug Test Tell Us
What Does the Drug Test Tell Us QUALITATIVE TOXICOLOGY TESTING for CLINICAL MANAGEMENT of the PATIENT Background The qualitative drug test is often referred to as the drug screen - a misnomer Testing performed
Urine Drug Testing. Why drug test? Set the Standard!
Urine Drug Testing Urine drug testing is a valuable tool for the physician when making treatment decisions. Patients and physicians benefit from safe and effective treatment of pain but there are always
Drug Utilization Is On The Rise
Objectives Identify the clinical issues related to opioid prescribing for chronic pain indications Define the clinical needs and expectations of urine drug testing in pain management Address preanalytical
URINE DRUG TESTING. Effective December 1 st, 2012
URINE DRUG TESTING Effective December 1 st, 2012 Policy Neighborhood Health Plan (NHP) reimburses medically appropriate urine drug testing (UDT) to detect the parent drug and/or its metabolite(s) to demonstrate
Drug Testing to Support Pain Management
NATIONAL REFERENCE LABORATORY Drug Testing to Support Pain Management 500 Chipeta Way, Salt Lake City, UT 84108 (800) 522-2787 (801) 583-2787 www.aruplab.com www.arupconsult.com ARUP is an enterprise of
Simultaneous Quantitation of 78 Drugs and Metabolites in Urine with a Dilute-And-Shoot LC MS-MS Assay
Journal of Analytical Toxicology 2015;1 12 doi:10.1093/jat/bkv024 Journal of Analytical Toxicology Advance Access published April 1, 2015 Article Simultaneous Quantitation of 78 Drugs and Metabolites in
Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)
Appendix D: Urine Drug Testing for Monitoring Opioid Therapy i. Monitoring opioid therapy with urine drug testing (UDT) ii. UDT algorithm for monitoring opioid therapy iii. UDT clinical vignettes iv. Frequently
2013 Annual Toxicology Report
213 Annual Toxicology Report Department of Justice Forensic Science Division Toxicology Department 2679 Palmer Street Missoula, MT 5988 DOJTOX@mt.gov Personnel Phil Kinsey Scott Larson Scott Schlueter
Update on Drug Impaired Driving. WTSC Impaired Driver Conference SeaTac, December 2006
Update on Drug Impaired Driving WTSC Impaired Driver Conference SeaTac, December 2006 12/4/2007 Alcohol, Drugs and Driving Household Survey, 2004 (prior year) Any Illicit Drug Use 19.9 Million 8.3% Marijuana
Appropriate Use of UDT to Improve Patient Care
Published on OpioidRisk (http://www.opioidrisk.com) Home > Urine Drug Testing Urine Drug Testing This guide provides: Download Entire Guide [1] Appropriate use of Urine Drug Testing (UDT) to improve patient
Pharmacology and Physiology (C105) Understanding Pharmacology and Physiology. The History of Drugs. The Neurobiology of Addiction.
Understanding Pharmacology and Physiology Knowledge of Pharmacology and Physiology is Crucial SAMHSA s Counselor Competencies What is Addiction? NIDA: Why Do People Use Drugs? From Abuse to Addiction Desired
Urine drug screens. Screening Methods
Screening Methods Urine drug screens Urine drug screens are generally performed using either immunoassays or gas chromatography-mass spectrometry (GC-MS). 2 Immunoassay UDS contain specific antibodies
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion
DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015
DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015 The signatory parties recognize that drug abuse is an illness that creates serious problems for workers, their families, the workplace and
76641 Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete 76642 limited
2015 CPT Code Update The ACR, either alone or in conjunction with other specialty societies, worked on a number of code proposals for the 2015 code cycle. This update provides a listing of code changes
Urine Drug Testing Methadone 101 Methadone for hospitalists
Urine Drug Testing Methadone 101 Methadone for hospitalists Dr. Patricia Mark MB, BCh LEARNING OBJECTIVES Clarify the purpose of urine drug testing Distinguish between UDT for detection of illicit drug
July 14, 2014. Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
ASCP s Statements before the Centers for Medicare and Medicaid Services Regarding Recommendations for Crosswalking/Gapfilling New CPT s for the CLFS for CY 2015 and the Revaluation of the Clinical Laboratory
Central Government Laboratory Department of Health and Environment
Central Government Laboratory Department of Health and Environment Overview who we are and what we do What is available and what is protocol for good science Sample collection Screening Tests Confirmation
MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy
MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy Purpose: To help safeguard employee health, provide a safe and productive workplace, and supply our people served with high quality service, Mosaic
CCW Task Order 16: Round 3 Clinical Condition Algorithms. Page 1 of 5 ICD-9 CODE DESCRIPTION ICD-9 CODE
DESCRIPTION 292 Drug-induced mental disorders 2920 Drug withdrawal 29211 Drug-induced psychotic disorder with delusions 29212 Drug-induced psychotic disorder with hallucinations 2922 Pathological drug
Local Coverage Determination (LCD) for Qualitative Drug Screening (L30574)
Local Coverage Determination (LCD) for Qualitative Drug Screening (L30574) Contractor Information Contractor Name First Coast Service Options, Inc. Back to Top Contractor Number 09102 Contractor Type MAC
Simultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method
Simultaneous Quantitation of 4 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method Xiang He and Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 76 Key Words TSQ Quantum Access
Patterns and Trends in Drug Abuse in Los Angeles County, California: 2013
Patterns and Trends in Drug Abuse in Los Angeles County, California: 2013 Mary-Lynn Brecht, Ph.D. 1 ABSTRACT A key finding in the Los Angeles area in this reporting period was the continuing increase in
Prescription Drugs: Impacts of Misuse and Accidental Overdose in Mississippi. Signe Shackelford, MPH Policy Analyst November 19, 2013
Prescription Drugs: Impacts of Misuse and Accidental Overdose in Mississippi Signe Shackelford, MPH Policy Analyst November 19, 2013 Center for Mississippi Health Policy Independent, non-profit organization
Technical Procedure for the Solid Phase Extraction of Acidic, Neutral and Basic Drugs for GC-MS Analysis
Technical Procedure for the Solid Phase Extraction of Acidic, Neutral and Basic Drugs for GC-MS Analysis 1.0 Purpose - This procedure specifies the required elements for the solid phase extraction of acidic,
LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories
LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic
POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
Drug Testing in the Pain Management Setting
Drug Testing in the Pain Management Setting September 27, 2011 Gwen McMillin, PhD, DABCC University of Utah, ARUP Laboratories Disclosure Laboratory director consultant for Clinical Lab Consulting, LLC
LC-MS for Pain Management Support
LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic
Substance Abuse Prevention and Treatment Agency March, 2012
Substance Abuse Prevention and Treatment Agency March, 2012 1 The mission of the Substance Abuse Prevention and Treatment Agency (SAPTA) is to reduce the impact of substance abuse in Nevada. SAPTA funds
Neurotransmitters Made Easy: The Mood Teeter-Totter
Neurotransmitters Made Easy: The Mood Brad Lander PhD, LICDC Clinical Director / Psychologist Talbot Hall - Addiction Medicine at The Ohio State University Wexner Medical Center Key Point #1 Thinking and
Local Coverage Determination (LCD): Qualitative Drug Testing ( L32050 )
Page 2 of 8 Local Coverage Determination (LCD): Qualitative Drug Testing ( L32050 ) Contractor Information Contractor Name Novitas Solutions, Inc. Contract Number 12502 Contract Type A and B MAC LCD Information
1.7.8.5 EFFECTIVE DATE: February 12, 2010, unless a later date is cited at the end of a section. [1.7.8.5 NMAC - Rp, 1.7.8.5 NMAC, 02/12/2010]
![1.7.8.5 EFFECTIVE DATE: February 12, 2010, unless a later date is cited at the end of a section. [1.7.8.5 NMAC - Rp, 1.7.8.5 NMAC, 02/12/2010]](/thumbs/21/1191525.jpg "1.7.8.5 EFFECTIVE DATE: February 12, 2010, unless a later date is cited at the end of a section. [1.7.8.5 NMAC - Rp, 1.7.8.5 NMAC, 02/12/2010]")
TITLE 1 CHAPTER 7 PART 8 GENERAL GOVERNMENT ADMINISTRATION STATE PERSONNEL ADMINISTRATION DRUG AND ALCOHOL ABUSE 1.7.8.1 ISSUING AGENCY: State Personnel Board. [1.7.8.1 NMAC - Rp, 1.7.8.1 NMAC, 02/12/2010]
PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications
PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications Primary Care & Specialist Prescribing Guidelines Introduction Partnership HealthPlan is a County Organized Health System covering
2013 IDAHO STATE POLICE FORENSIC SERVICES: TOXICOLOGY TRENDS
Toxicology Program Trends 213 213 IDAHO STATE POLICE FORENSIC SERVICES: TOXICOLOGY TRENDS Overview and Background This report discusses trends in the toxicology program, as well as the number of toxicology
REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS
EFFECTIVE DATE: 06/01/2013 REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS (FOR TESTING TO BE CONDUCTED IN CALIFORNIA [excluding the City of San
Drug Usage in Pilots Involved in Aviation Accidents Compared With Drug Usage in the General Population: From 1990 to 2005
DOT/FAA/AM-08/10 Office of Aerospace Medicine Washington, DC 20591 Drug Usage in Pilots Involved in Aviation Accidents Compared With Drug Usage in the General Population: From 1990 to 2005 Sabra R. Botch
Understanding Drug Screens & PharmCAS Drug Screening Program Overview. Suzi Arant, Senior Business Developer July 8, 2011
Understanding Drug Screens & PharmCAS Drug Screening Program Overview Suzi Arant, Senior Business Developer July 8, 2011 Presentation Overview Drug Screening in Healthcare Drug Screening Panels Drugs of
Clinic Reference Guide
Clinic Reference Guide 2010 Alliance Toxicology LLC PO Box 5000, PMB 190 Rancho Santa Fe, CA 92067 AllianceToxicologyLLCprovidesclinicaldrugtestingservicesforphysicians.Our companyprovidesacomprehensivedrugtestingpanelwhichincludesover40
Drug-Testing Program. Overview
Sunnyvale Independent School District DrugTesting and Rehabilitation Program 20132014 DrugTesting Program Overview The District requires drug testing of any student in grade 912 who chooses to participate
DRUG DRIVING OFFENCES
DRUG DRIVING OFFENCES Taking drug can affect body and mind coordination that can significantly impair the ability to drive a motor vehicle. Road Traffic Ordinance (Cap 374) was amended in 2011 in order
METHADONE SUBSTITUTION THERAPY PROGRAM AND TOXICOLOGICAL STUDIES
METHADONE SUBSTITUTION THERAPY PROGRAM AND TOXICOLOGICAL STUDIES Halina MATSUMOTO, El bieta WO NY, Anna DZIKLIÑSKA, Ma³gorzata ABRAMOWSKA Laboratory of Psychopharmacology, 1st Department of Psychiatry,
MA Bulletin 01-06-06 Keystone Mercy Health Plan is implementing the following changes:
September 1, 2006 Dear Keystone Mercy Provider: Effective July 17, 2006, the Pennsylvania Department of Public Welfare (DPW) has end-dated several local procedure codes pertaining to services offered in
SMART DISCHARGE. Client s Name: Client ID: Partial Hospitalization Clinically Managed Medium Intensity Residential Treatment
SMART DISCHARGE Client s Name: Client ID: DATE OF DISCHARGE: Reason for Discharge Completed Treatment no further treatment needed Completed Treatment Plan/Referred Incomplete Client Left Before Completing
1. Which of the following would NOT be an appropriate choice for postoperative pain. C. Oral oxycodone 5 mg po every 4 to 6 hours as needed for pain
Pain Management 1 Chapter 34. Pain Management, Self-Assessment Questions 1. Which of the following would NOT be an appropriate choice for postoperative pain management in a patient dependent on opioids?
Horizon Blue Cross Blue Shield of New Jersey 2012 Radiation Therapy Payment Rules
55875 55876 55876 Description Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or wout cytosocopy 55920 Placement of interstitial device(s)
Urine Drug Testing of Chronic Pain Patients: Licit and Illicit Drug Patterns
Urine Drug Testing of Chronic Pain Patients: Licit and Illicit Drug Patterns Edward J. Cone* Johns Hopkins School of Medicine, Baltimore, Maryland Yale H. Caplan National Scientific Services, Baltimore,
Urine Drug Testing In Pain Management and Opioid Abuse Treatment Corporate Medical Policy
Urine Drug Testing In Pain Management and Opioid Abuse Treatment Corporate Medical Policy File name: Urine Drug Testing in Pain Management and Opioid Abuse Treatment File code: UM.SPSVC.09 Origination:
Managing Chronic Pain in Adults with Substance Use Disorders
Question from chapter 1 Managing Chronic Pain in Adults with Substance Use Disorders 1) What is the percent of chronic pain patients who may have addictive disorders? a) 12% b) 22% c) 32% d) 42% 2) Which
CPT Code Changes for 2015 PATHOLOGY/LABORATORY
Changes for 2015 PATHOLOGY/LABORATORY Rick Oliver, CPCO, CPC, MT(ASCP) Compliance Director- Laboratory and Pathology McKesson Business Performance Services This commentary is a summary prepared by McKesson
Generation Drug Free Workplace Policy for Contractor Personnel
Generation Drug Free Workplace Policy for Contractor Personnel Revision: 04 Date: 05-06-15 Submitted: Electronic approval pages are archived in CSR Portfolio. Contact K. Kemp for a copy. Reviewed: Reviewed:
The Drug Evaluation and Classification Program
The Drug Evaluation and Classification Program International Association of Chiefs of Police Drug Evaluation and Classification (DEC) Program The Drug Evaluation and Classification (DEC) Program is a transportation
Rationale for Urine Drug Testing (UDT)
Rationale for Urine Drug Testing (UDT) Help to identify drug misuse/addiction Prior to starting opioid treatment Assist in assessing adherence during opioid therapy As requirement of therapy w/ an opioid
After seeing a patient on a Diversion Alert installment..
After seeing a patient on a Diversion Alert installment.. Recommendations from Dr. James Berry of Mercy Recovery Center OVERVIEW OF DIVERSION Manufacture Distribution Pharmacy Patient End -user OPPORTUNITIES
a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes einforcement
Drug Abuse (chapter 18) 1. Definitions iti a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes 2. Neural Mechanisms of Re einforcement a. mesolimbic dopamine system b.
CERTIFICATE OF COMPLIANCE OF
CERTIFICATE OF COMPLIANCE OF Name of Contractor Company GOLDEN TRIANGLE CONTRACTOR SUBSTANCE AND ALCOHOL ABUSE PROGRAM November 2002 Edition Adopted and implemented by [Name of Contractor Company] ( Company
Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia
Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE
URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE
URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE The likelihood of surprises leads to the recommendation that virtually all patients who receive chronic opioids should be tested initially, occasionally
Indiana State Department of Toxicology 2012 Annual Report
Indiana State Department of Toxicology 2012 Annual Report Pictured on the cover is the State of Indiana Forensic and Health Sciences Laboratories facility housing the Indiana State Department of Toxicology.
LAKE COUNTY SCHOOLS RECEIPT OF DRUG-FREE WORKPLACE POLICY
LAKE COUNTY SCHOOLS RECEIPT OF DRUG-FREE WORKPLACE POLICY I hereby acknowledge receipt of the Lake County School Board s Drug-Free Workplace Policy. I Understand that the name, address and telephone number
NEONATAL ABSTINENCE SYNDROME. Osama Naga, M.D. PGY2
NEONATAL ABSTINENCE SYNDROME Osama Naga, M.D. PGY2 Objective: Describe the common causes of NAS Clinical Presentation Diagnosis Identify the different scoring system for pharmacologic therapy Minimize
Drug Abuse Trends in Miami-Dade County, Florida: 2009-2010
Drug Abuse Trends in Miami-Dade County, Florida: 2009-2010 James N. Hall 1 ABSTRACT Cocaine consequences as a proportion of all drug problems continue to be higher in South Florida than in most of the
American Dental Association Providers Clinical Support System on Opioid Therapies Webinar
American Dental Association Providers Clinical Support System on Opioid Therapies Webinar Friday, May 23, 2014 2:00 PM (CDT) Funding for this initiative was made possible (in part) by Providers' Clinical
Alcoholism, Drug Addiction, and the Road to Recovery
Alcoholism, Drug Addiction, and the Road to Recovery Life on the Edge Barry Stimmel, MD The Haworth Medical Press An Imprint of The Haworth Press, Inc. New York London Oxford CONTENTS Preface Acknowledgments
Drugs, The Brain, and Behavior
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major categories
Monitoring Program (DMP) heroin purchase data (edited versions) were also utilized. Data were also obtained from the Threat Assessment Report
Drug Abuse Trends in the Seattle/King County Area: 2011 Caleb Banta-Green 1, T. Ron Jackson 2, Steve Freng 3, Michael Hanrahan 4, Geoff Miller 8, Steve Reid 5, John Ohta 6, Mary Taylor 7, Richard Harruff
OPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
Prevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies
Downloaded from orbit.dtu.dk on: Nov 25, 2015 Prevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies Bernhoft, Inger Marie; Hels, Tove Publication
Listed below are some of the reasons given by users to describe why they take drug(s): An escape from problems, either at home, school or work.
Once drug use comes into the equation, inhibitions that normally protect the individual effectively go out of the window and leave the user feeling high or buzzing. Situations, incidents or behaviours
What Americans Believe. Grant Beardsley, MS, MT(ASCP) 10/12/2015. Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse
Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse Grant D. Beardsley, M.S., MT(ASCP) Clinical Toxicologist, Grant Beardsley, MS, MT(ASCP) I have nothing to disclose. I
OU MEDICAL CENTER Human Resource Policy and Procedure Manual. Subject: Drug and Alcohol
OU MEDICAL CENTER Human Resource Policy and Procedure Manual Subject: Drug and Alcohol Section: HR 6-10 Page: 1 of 5 Origination Date: 6/2004 Revision Date: 2/2006, 9/2008, 7/2009 Coverage: All OUMC employees
CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES
CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES Vina SPIEHLER 1, Dene BALDWIN 2, Christopher HAND 2 1 DABFT, Newport Beach, United States of America 2 Cozart